This new device offers the advantage of a lower frame height, which reduces the chance of coronary occlusion. The delivery system is totally motorized and the valve can be repositioned. In addition, the sheath is “14 F” for all valve sizes (23, 26 and 29mm). 203 patients were included, all with severe aortic stenosis...
We thank all the speakers of the Chile 2016 Sessions who shared their presentations to contribute to our mission of promoting the dissemination of information from research and clinical practice in Interventional Cardiology. You can read and/or download them below Lluberas, Ricardo. “Role of pharmacovasive therapy in the treatment of IAMcEST. Implications for Latin...
Courtesy of Dr. Agustín Vecchia. Surgery is the treatment of choice for patients with symptomatic aortic insufficiency and/or ventricular dilatation or decreased ventricular function. The broad implementation of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis, the emergence of new devices, and the experience acquired by operators have brought this treatment to off-label indications such...
Original title: 5 Years Experience With Trancatheter Tranaspical Mitral Valve –in Valve Implantation for Bioprosthetic Valve Dysfunction Reference: Anson Cheung et al. J Am Coll Cardiol 2013;61:1759–66. Percutaneous valves development, first aortic and now mitral, has brought an opportunity to improve life quality and extend life for high risk non-surgical patients. 23 patients received transapical implantation in mitral...
Original title: 5-Year Outcome After Aortic Valve Implantation Reference: Stefan Toggweiler, et al. J Am Coll Cardiol 2013;61:413–9 Percutaneous aortic valve implantation (TAVI) is now a valid strategy as we know its short and medium term evolution but we do not have enough information available about the long term. The aim of this study was to analyze the...
Original title: Impact of Post-Procedural Aortic Regurgitation on Mortality Alter Trancatheter Aortic Valve Implantation Reference: Kentaro Hayashida, et al. J Am Coll Interv 2012;5:1247-56 Transcatheter aortic valve implantation (TAVI) sprung up as a valid strategy to treat patients with severe high risk AS (aortic stenosis). However, residual aortic regurgitation (post AR) and post-dilation remain unsolved. Between October 2006...
Reference: Durand E. et al (JACC CV interventions 2012 in press)1 When percutaneous aortic valve replacement (AVR) first began the procedure required a large-bore sheath (22-24 F), being the most frequent surgical strategy when using general anesthesia. Continuous technological advances achieved the miniaturization of devices which allow the procedure to be performed with a much...